Abstract: There are provided, inter alia, compositions and methods for treatment of chemoresistant cancer (breast cancer). The methods include administering to a subject in need a therapeutically effective amount of a chemotherapeutic agent and a ROR-1 antagonist. Further provided are pharmaceutical compositions including chemotherapeutic agent, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the chemotherapeutic agent is paclitaxel and the ROR-1 antagonist is cirmtuzumab.

Abstract: Disclosed are an anti-ROR2 antibody and a use thereof. The anti-ROR2 antibody includes: a light chain variable region with amino acid sequence shown in CSASSSVSYMHWYQ, IYDTSKLAS and CQQWSSNPPTFGAG, and a heavy chain variable region with amino acid sequence shown in YTITSYLMHWV, LEWIGYINPYNDGTKYNEKFKDKAT and CARSDVYYGVRFAYWGQG; a light chain variable region with amino acid sequence shown in CKASQNVGTNVAWFQ, IYLASYRYS and CQQYNSYPLTFGGG, and a heavy chain variable region with amino acid sequence shown in YTFTNYWIQWM, LEWIGEINPSNGRTDYNEKFKNRAT and CANYRPGYWGQG; and a light chain variable region with amino acid sequence shown in CSASSSISYMYWYQ, IYDTSILAS and CQQWSSYPFTFGSG, and a heavy chain variable region with amino acid sequence shown in YTFTSYLIHWV, LEWIGYINPYNDGTKYNEKFKDKAT and CARSDVYYGVRFAYWGQG.

Abstract: Disclosed are an anti-ROR2 antibody and a use thereof. The anti-ROR2 antibody includes at least one of the following: (1) a light chain variable region with amino acid sequence shown in CSASSSVTYTYWYQ, IYDTSNLAS and CQQWSSYPFTFGSG, and a heavy chain variable region with amino acid sequence shown in YTFTSYLMHWV, LEWIGYINPYNDGTKYNEKFKDKAT and CARSDVYYGVRFAYWGQG; compared with (1), the antibody or antigen-binding fragment has an amino acid sequence with at least one conservative amino acid substitution.

Abstract: There are provided, inter alia, compositions and methods for treatment of chemoresistant cancer (breast cancer). The methods include administering to a subject in need a therapeutically effective amount of a chemotherapeutic agent and a ROR-1 antagonist. Further provided are pharmaceutical compositions including chemotherapeutic agent, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the chemotherapeutic agent is paclitaxel and the ROR-1 antagonist is cirmtuzumab.

Abstract: Compositions including an antibody specific for CD44 are provided. These antibodies specifically bind to hematologic malignant cells. Methods to use the CD44 antibodies to target cells expressing CD44 for therapeutic and diagnostic purposes are also provided.

Abstract: Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.

Abstract: Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.